About the Company
paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRTK News
Why Paratek Pharmaceuticals Stock Is Up Today
S hares of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company, are up Tuesday after the company announced that it entered into a definitive agreement to be ...
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates
Paratek Pharmaceuticals (PRTK ... One other stock from the same industry, Precigen, Inc. (PGEN), is yet to report results for the quarter ended March 2023. The results are expected to be released ...
ArriVent Appoints Kristine Peterson to its Board of Directors
“I am excited to work alongside ArriVent’s talented management team and Board of Directors to help address the unmet needs of cancer patients,” said Ms. Peterson. “I look forward to providing ...
What is the Pipeline for Gram-negative Pathogens?
and Timothy Babinchak (Wyeth Pharmaceuticals); Ann Macone and Robert Arbeit (Paratek Pharmaceuticals, Inc.); Karen Bush and Robert Flamm (Johnson & Johnson); Brian Dannemann (Hoffmann La Roche ...
Elite Pharmaceuticals, Inc. (ELTP)
Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript February 15, 2024 Elite Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
LIFE aTyr Pharma, Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is ...
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
Amphastar Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
CRVS Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers ...
Alnylam Pharmaceuticals Inc ALNY
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pharmaceuticals / Health Products Summary
Now showing summary data for the 2024 election cycle. Now showing data for the election cycle. The pharmaceutical and health products industry — including not only drug manufacturers but also dealers ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...